• The full-service CRO

    The CRO of choice
    by the leading Investigators

    and Sites

    Serving clients ranging
    from Big Pharma

    to Start-ups

    Combining Global Coverage with true Local Expertise

    In the United States, Europe, Russia and Asia, since 2001

    Continue to the website
    Download brochure

GCT to Manage Phase III COVID-19 Study

Global Clinical Trials is adding yet another COVID-19 clinical trial to its Infectious Disease portfolio. As a part of a multi-national project, GCT will manage the double-blind Phase III study in adult patients with COVID-19 in Russia.

After a thorough feasibility analysis, GCT clinical team together with the Sponsor selected the clinical sites with the most enrollment potential.

August 30, 2021

End of Enrollment for the Sore Throat Trial

The enrollment was completed for a phase IV, multicenter, randomized, non-inferiority trial by reaching the study-wide goal of including 360 patients.

GCT is responsible for managing project in Russia where the patient enrolment began in August 2020.

July 29, 2021

First Patient in Idiopathic Pulmonary Fibrosis Study

The first patient has been included in this clinical trial in Russia. The study is a Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy of IP aiming to help those suffering from IPF.

Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. When it occurs, scar tissue (fibrosis) is accumulated in the lungs, making it very difficult for the lungs to transport oxygen efficiently into the bloodstream.

July 13, 2021

GCT to Participate in a New Global COVID-19 Study

GCT has just been awarded a new clinical study related to SARS-CoV-2.

It is a double-blind, randomized, placebo-controlled, phase II study in hospitalized patients infected with severe acute respiratory syndrome-coronavirus-2. The Sponsor is a Swiss Biotech. For this study, 150 patients will be enrolled at the Russian sites.

July 28, 2021

First Patient In Endometriosis Clinical Trial in Ukraine

Global Clinical Trials announces the first successful screening in the endometriosis study.

It is a Phase III double-blind, three-arm superiority study in 200+ subjects that is being conducted in Ukraine. The study aims to assess the safety and efficacy of the Investigational Product (IP) for treatment of endometriosis in women of reproductive age.

July 6, 2021

GCT Celebrates 20 Years of Successfully Managing Clinical Trials

Global Clinical Trials, LLC (“GCT”) is a premier contract research organization providing clinical services in the U.S., Europe, and Asia.

The company is delighted to announce the celebration of 20 years helping small and large pharma, biotech and medical device companies run their clinical studies.

In the following months, GCT will be publishing media content, including the stories of GCT employees and empirical lessons that contributed most to the growth of the company and its service offerings.

June 23, 2021

Meet our clients

All trademarks, brand names and logotypes are intellectual property of their respective owners.

Upcoming meetings

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.